Format

Send to:

Choose Destination
See comment in PubMed Commons below
Anticancer Res. 2013 Dec;33(12):5517-24.

YKL-40 and mesothelin in the blood of patients with malignant mesothelioma, lung cancer and asbestosis.

Author information

  • 1Department of Clinical and Experimental Medicine, University of Parma, Via Gramsci 14, 43123 Parma, Italy. massimo.corradi@unipr.it.

Abstract

BACKGROUND/AIM:

In the diagnosis of malignant mesothelioma (MM) there still is a lack of specific and sensitive screening biomarkers: this study examined the discriminatory power of a panel of serum/plasma biomarkers.

PATIENTS AND METHODS:

The study involved four groups: (a) individuals previously exposed to asbestos with asbestosis; (b) patients with MM; (c) patients with non-small cell lung cancer; and (d) controls without any evidence of malignancy. The concentrations of mesothelin, chitinase-3-like-1 (YKL-40), vascular endothelial growth factor (VEGF), endothelin-1, interleukin-8 (IL-8) and fibulin-3 in the serum of patients were determined.

RESULTS:

Patients with MM had significantly higher serum levels of mesothelin (p<0.001), YKL-40 (p<0.001), IL-8 (p<0.001) and VEGF (p<0.01) than controls. The cut-off point for MM was 1.26 nM for mesothelin alone, and 167 pg/ml for YKL-40 alone; the presence of both markers above these cut-off levels improved diagnostic specificity.

CONCLUSION:

The addition of YKL-40 may improve the specificity of mesothelin measurements alone for detecting patients with MM.

KEYWORDS:

Malignant mesothelioma; YKL-40; lung cancer; mesothelin

PMID:
24324091
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk